Stockreport

Praxis Precision Medicines (PRAX): Reassessing Valuation After EMBOLD Success and Ulixacaltamide Pre-NDA Milestone [Yahoo! Finance]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF Praxis Precision Medicines (PRAX) just hit a double inflection point, with its EMBOLD trial for relutrigine stopped early for efficacy and a successful pre-NDA meeting f [Read more]